NEW YORK, June 28, 2021 /PRNewswire/ -- Immunic,
Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical
company developing a pipeline of selective oral immunology
therapies aimed at treating chronic inflammatory and autoimmune
diseases, today announced participation in the following
scientific, industry and investor conferences in July:
- June 30-July 3: The
International Federation of Psoriasis Association's 6th
World Psoriasis & Psoriatic Arthritis Conference 2021. Dr.
Thomas M Polasek, Clinical Pharmacology Registrar, Royal Adelaide
Hospital, Australia, will present
the first clinical experience with IMU-935, an orally available,
selective inverse agonist of RORγt. The poster presentation will be
accessible on the "Events and Presentations" section of Immunic's
website at: ir.imux.com/events-and-presentations.
-
- Abstract Number: 36568
- Title: Safety, tolerability and pharmacokinetics of single
oral doses of IMU-935 in healthy volunteers: First clinical
experience with an orally available small molecule inhibitor of
IL-17
- Session Title: Current and new therapeutic modalities
- Session Number: 4
- July 2-3 and 8-10, 2021: 16th
Congress of ECCO (European Crohn's and Colitis Organization).
Members of Immunic's management and clinical teams will attend the
virtual conference.
- July 13-14: Ladenburg Thalmann
Healthcare Conference. Daniel
Vitt, Ph.D., Chief Executive Officer and President of
Immunic, will present a company overview on Tuesday, July 13, at 10:00
am ET. A live audio webcast of the presentation will be
available on the "Events and Presentations" section of Immunic's
website at: ir.imux.com/events-and-presentations. An archived
replay will be available on the company's website for a period of
90 days.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a
clinical-stage biopharmaceutical company with a pipeline of
selective oral immunology therapies aimed at treating chronic
inflammatory and autoimmune diseases. The company is developing
three small molecule products: its lead development program,
IMU-838, a selective immune modulator that inhibits the
intracellular metabolism of activated immune cells by blocking the
enzyme DHODH and exhibits a host-based antiviral effect, is
currently being developed as a treatment option for multiple
sclerosis, ulcerative colitis, Crohn's disease, and primary
sclerosing cholangitis. IMU-935, a selective inverse agonist of the
transcription factor RORγt, is targeted for development in
psoriasis and Guillain-Barré syndrome. IMU-856, which targets the
restoration of the intestinal barrier function, is targeted for
development in diseases involving bowel barrier dysfunction. For
further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
management's participation in scientific, industry and investor
conferences. Immunic may not actually achieve the plans, carry out
the intentions or meet the expectations or projections disclosed in
the forward-looking statements and you should not place undue
reliance on these forward-looking statements. Such statements are
based on management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the
COVID-19 pandemic, risks and uncertainties associated with the
ability to project future cash utilization and reserves needed for
contingent future liabilities and business operations, the
availability of sufficient resources to meet business objectives
and operational requirements, the fact that the results of earlier
studies and trials may not be predictive of future clinical trial
results, the protection and market exclusivity provided by
Immunic's intellectual property, risks related to the drug
development and the regulatory approval process and the impact of
competitive products and technological changes. A further list and
descriptions of these risks, uncertainties and other factors can be
found in the section captioned "Risk Factors," in the company's
Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on
February 26, 2021, and in the
company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov or ir.imux.com/sec-filings. Any forward-looking
statement made in this release speaks only as of the date of this
release. Immunic disclaims any intent or obligation to update these
forward-looking statements to reflect events or circumstances that
exist after the date on which they were made. Immunic expressly
disclaims all liability in respect to actions taken or not taken
based on any or all the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 322 2216
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 781 639 1910
kaplan@kogspr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunic-inc-to-participate-in-scientific-industry-and-investor-conferences-in-july-301320510.html
SOURCE Immunic, Inc.